Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
32.33B
Market cap32.33B
Price-Earnings ratio
-102.55
Price-Earnings ratio-102.55
Dividend yield
Dividend yield
Average volume
1.86M
Average volume1.86M
High today
$240.18
High today$240.18
Low today
$233.77
Low today$233.77
Open price
$238.62
Open price$238.62
Volume
823.71K
Volume823.71K
52 Week high
$241.28
52 Week high$241.28
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

With a market cap of 32.33B, Natera(NTRA) trades at $235.00. The stock has a price-to-earnings ratio of -102.55.

During the trading session on 2025-12-02, Natera(NTRA) shares reached a daily high of $240.18 and a low of $233.77. At a current price of $235.00, the stock is +0.5% higher than the low and still -2.2% under the high.

Trading activity shows a volume of 823.71K, compared to an average daily volume of 1.86M.

The stock's 52-week range extends from a low of $125.38 to a high of $241.28.

The stock's 52-week range extends from a low of $125.38 to a high of $241.28.

NTRA News

Simply Wall St 17h
Have Insiders Sold Natera Shares Recently?

Some Natera, Inc. ( ) shareholders may be a little concerned to see that the Lead Independent Director, Roelof Botha, recently sold a substantial US$18m worth o...

Have Insiders Sold Natera Shares Recently?
Simply Wall St 5d
Will Flatiron Partnership Give Natera a New Edge in OncoEMR Integration?

Flatiron Health recently announced the integration of Natera's oncology testing portfolio into its OncoEMR platform, enabling electronic ordering and results de...

Will Flatiron Partnership Give Natera a New Edge in OncoEMR Integration?
TipRanks 7d
Natera price target raised to $250 from $240 at JPMorgan

JPMorgan raised the firm’s price target on Natera (NTRA) to $250 from $240 and keeps an Overweight rating on the shares. The firm updated the company’s model....

Analyst ratings

91%

of 22 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.